来凯医药-B(02105)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02105 来凯医药-B

交易中 05-09 13:07:58

6.310

+0.360

+6.05%

最高6.810	最低5.980	成交量777.25万
今开5.980	昨收5.950	日振幅13.95%
总市值24.62亿	流通市值24.62亿	总股本3.90亿
成交额5,000万	换手率1.99%	流通股本3.90亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02105","market":"HK","secType":"STK","nameCN":"来凯医药-B","latestPrice":6.31,"timestamp":1715231199563,"preClose":5.95,"halted":0,"volume":7772500,"delay":0,"floatShares":390100350,"shares":390100350,"eps":-1.8160077,"marketStatus":"交易中","marketStatusCode":2,"change":0.36,"latestTime":"05-09 13:07:58","open":5.98,"high":6.81,"low":5.98,"amount":49998090,"amplitude":0.139496,"askPrice":6.34,"askSize":500,"bidPrice":6.31,"bidSize":1500,"shortable":0,"etf":0,"ttmEps":-1.8160077410197892,"exchange":"SEHK","tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1715242200000},"adr":0,"listingDate":1687968000000,"adjPreClose":5.95,"openAndCloseTimeList":[[1715218200000,1715227200000],[1715230800000,1715241600000]],"volumeRatio":12.368535,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02105/wiki","defaultTab":"wiki","newsList":[{"id":"2434803997","title":"来凯医药科技（上海）有限公司药品申请临床试验默示许可获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2434803997","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2434803997?lang=zh_cn&edition=full","pubTime":"2024-05-09 11:03","pubTimestamp":1715223782,"startTime":"0","endTime":"0","summary":"5月9日，据CDE官网消息，来凯医药科技(上海)有限公司联合申请药品“LAE102注射液”，获得临床试验默示许可，受理号CXSL2400155。公示信息显示，药品“LAE102注射液”适应症：超重和/或肥胖。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050911054687e2afa0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050911054687e2afa0&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2434033083","title":"东曜药业-B盘中异动 早盘股价大跌8.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2434033083","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2434033083?lang=zh_cn&edition=full","pubTime":"2024-05-09 10:38","pubTimestamp":1715222335,"startTime":"0","endTime":"0","summary":"2024年05月09日早盘10时38分，东曜药业-B股票出现异动，股价大幅跳水8.99%。截至发稿，该股报1.720港元/股，成交量4.08万股，换手率0.01%，振幅12.70%。东曜药业-B股票所在的生物技术行业中，整体涨幅为2.15%。其相关个股中，再鼎医药、来凯医药-B、锦欣生殖涨幅较大，振幅较大的相关个股有来凯医药-B、圣诺医药-B、再鼎医药，振幅分别为13.95%、13.43%、13.37%。东曜药业-B公司简介：东曜药业股份有限公司是一家主要从事开发及商业化肿瘤药物及疗法的公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405091038557926a96b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405091038557926a96b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2434033489","title":"来凯医药－Ｂ(02105)股价显著上升11.765%，现价港币$6.65","url":"https://stock-news.laohu8.com/highlight/detail?id=2434033489","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2434033489?lang=zh_cn&edition=full","pubTime":"2024-05-09 10:24","pubTimestamp":1715221440,"startTime":"0","endTime":"0","summary":"[上升股]来凯医药－Ｂ(02105) 股价在上午10:24比前收市价显著上升11.765%，现股价为港币$6.65。至目前为止，今日最高价为$6.65，而最低价为$5.98。总成交量为343.5万股，总成交金额为港币$2.171千万。","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180205152552334_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180205152552334_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2405091340/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2432764891","title":"来凯医药－Ｂ(02105)股价上升5.016%，现价港币$6.49","url":"https://stock-news.laohu8.com/highlight/detail?id=2432764891","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2432764891?lang=zh_cn&edition=full","pubTime":"2024-05-02 13:50","pubTimestamp":1714629000,"startTime":"0","endTime":"0","summary":"[上升股]来凯医药－Ｂ(02105) 股价在下午01:50比前收市价上升5.016%，现股价为港币$6.49。至目前为止，今日最高价为$6.49，而最低价为$6.1。总成交量为26.75万股，总成交金额为港币$167.332万。","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180205152552334_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180205152552334_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2405024237/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2430241272","title":"来凯医药-B04月26日主力资金流入26万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2430241272","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430241272?lang=zh_cn&edition=full","pubTime":"2024-04-26 16:16","pubTimestamp":1714119379,"startTime":"0","endTime":"0","summary":"04月26日, 来凯医药-B股价涨3.87%，报收6.18元，成交金额3170万元，换手率1.34%，振幅9.41%，量比0.72。来凯医药-B今日主力资金净流入26万元，连续3日净流入，上一交易日主力净流入106万元，今日环比减少75.47%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为75.00%，平均涨幅为10.54%。该股近5个交易日上涨19.08%，主力资金累计净流入348万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入295万元，其中净流入天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042616170887b2a1cd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042616170887b2a1cd&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430089444","title":"创新药概念股表现强劲：来凯医药-B领涨10.34%，科济药业-B涨8.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430089444","media":"和讯网","top":-1,"share":"https://www.laohu8.com/m/news/2430089444?lang=zh_cn&edition=full","pubTime":"2024-04-25 12:20","pubTimestamp":1714018845,"startTime":"0","endTime":"0","summary":"【医药股早盘大幅上涨，创新药概念股表现强劲】 创新药概念股早盘大幅上涨，市场反应热烈。来凯医药-B涨幅领先，达到10.34%，股价报6.51港元。科济药业-B紧随其后，涨幅为8.32%，股价报5.47港元。 荣昌生物同样表现不俗，股价上涨6.46%，报31.30港元。此外，君实生物也录得5.04%的涨幅，股价攀升至10.22港元。市场对创新药概念股的追捧，反映了投资者对于医药行业创新和发展前景的高度认可。 随着医药行业的持续发展，创新药概念股有望继续保持强劲的增长势头。投资者可密切关注相关公司的业绩表现和市场动态，把握投资机会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042513100987ad93aa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042513100987ad93aa&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430457514","title":"创新药概念股走高 来凯医药-B涨超10%科济药业-B涨超8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430457514","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2430457514?lang=zh_cn&edition=full","pubTime":"2024-04-25 11:42","pubTimestamp":1714016542,"startTime":"0","endTime":"0","summary":"创新药概念股早盘持续走高，来凯医药-B（02105）上涨10.34%，报6.51港元；科济药业-B（02171）上涨8.32%，报5.47港元；荣昌生物（09995）上涨6.46%，报31.30港元；君实生物（01877）上涨5.04%，报10.22港元。\n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-04-25/doc-inasziaa7688096.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-04-25/doc-inasziaa7688096.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430443247","title":"港股异动 | 创新药概念股走高 科济药业-B(02171)涨超11% 创新药迎来全流程支持机制","url":"https://stock-news.laohu8.com/highlight/detail?id=2430443247","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430443247?lang=zh_cn&edition=full","pubTime":"2024-04-25 11:17","pubTimestamp":1714015021,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，创新药概念股持续走高，截至发稿，科济药业-B(02171)涨10.3%，报5.57港元；来凯医药-B(02105)涨9.15%，报6.44港元；荣昌生物(09995)涨6.29%，报31.25港元；君实生物(01877)涨5.65%，报10.28港元。甬兴证券指出，2023年医保基金运行总体平稳，该行认为随着国家医保局建立覆盖申报、评审、测算、谈判等全流程的创新药支持机制，更多新药好药有望纳入医保，创新药研发相关企业有望受益。东海证券表示，今年以来包括对创新药的明确支持、集采续约条款的持续优化等，行业政策向好态势明显；二季度以后板块整体有望持续转暖向好。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1109550.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429150445","title":"来凯医药-B04月23日遭主力抛售50万元 环比增加733.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429150445","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429150445?lang=zh_cn&edition=full","pubTime":"2024-04-23 16:16","pubTimestamp":1713860179,"startTime":"0","endTime":"0","summary":"04月23日, 来凯医药-B股价涨12.92%，报收6.03元，成交金额6896万元，换手率2.98%，振幅20.04%，量比1.76。来凯医药-B今日主力资金净流出50万元，连续5日净流出，上一交易日主力净流出6万元，今日环比增加733.33%。该股近5个交易日下跌7.21%，主力资金累计净流出303万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流入82万元，其中净流入天数为5日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042316165687a531fe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042316165687a531fe&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429153834","title":"港股异动 | 医药股午后拉升走强 创新药政策向好态势明显 二季度后板块有望持续转暖","url":"https://stock-news.laohu8.com/highlight/detail?id=2429153834","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429153834?lang=zh_cn&edition=full","pubTime":"2024-04-23 13:55","pubTimestamp":1713851752,"startTime":"0","endTime":"0","summary":"消息面上，近日，北京市医保局印发《北京市支持创新医药高质量发展若干措施》。东海证券近日研报指出，今年以来包括对创新药的明确支持、集采续约条款的持续优化等，行业政策向好态势明显；二季度以后板块整体有望持续转暖向好。中长期来看，持续看好创新药、特色器械等代表新质生产力发展方向的投资机会；中短期来看，重点关注品牌中药、连锁药店、血制品等低估值、高股息，成长稳健的相关板块及个股的投资机会。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1107395.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429131225","title":"来凯医药-B现涨超7% 肥胖适应症新药近期在美获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2429131225","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2429131225?lang=zh_cn&edition=full","pubTime":"2024-04-23 11:53","pubTimestamp":1713844433,"startTime":"0","endTime":"0","summary":"来凯医药-B（02105）早盘急速拉升，上涨7.30%，现报5.73港元，成交额2335.59万港元。\n　　来凯医药近期宣布，其自主研发的LAE102（ActRIIA单克隆抗体）已获得美国食品和药品管理局（FDA）的新药临床试验（IND）批准，用于治疗肥胖症患者。\n　　华创证券此前指出，全球首创的ActRIIA单抗LAE102能够增肌减脂，有潜力和GLP-1RA配合使用，市场潜力巨大并具备国际化价值。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-04-23/doc-inasuuvx0087351.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-04-23/doc-inasuuvx0087351.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429713672","title":"港股异动 | 来凯医药-B(02105)涨超8% 肥胖适应症新药近期在美获批临床 今年核心管线具多项催化剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2429713672","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429713672?lang=zh_cn&edition=full","pubTime":"2024-04-23 11:24","pubTimestamp":1713842664,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，来凯医药-B涨超8%，截至发稿，涨7.3%，报5.73港元，成交额2063.95万港元。消息面上，来凯医药近期宣布，其自主研发的LAE102已获得美国食品和药品管理局的新药临床试验批准，用于治疗肥胖症患者。华创证券此前指出，全球首创的ActRIIA单抗LAE102能够增肌减脂，有潜力和GLP-1RA配合使用，市场潜力巨大并具备国际化价值。太平洋证券则指出，2024 年公司核心管线具有多项催化剂。1）LAE102用于肥胖适应症的IND计划24H2启动首次人体临床研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1107358.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429136254","title":"来凯医药－Ｂ(02105)股价上升5.056%，现价港币$5.61","url":"https://stock-news.laohu8.com/highlight/detail?id=2429136254","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2429136254?lang=zh_cn&edition=full","pubTime":"2024-04-23 11:09","pubTimestamp":1713841740,"startTime":"0","endTime":"0","summary":"[上升股]来凯医药－Ｂ(02105) 股价在上午11:09比前收市价上升5.056%，现股价为港币$5.61。至目前为止，今日最高价为$5.61，而最低价为$5.26。总成交量为137.25万股，总成交金额为港币$748.056万。","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20190515141040914_s.png","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20190515141040914_s.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2404231964/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2428559081","title":"来凯医药-B04月18日遭主力抛售58万元 环比增加190.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2428559081","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428559081?lang=zh_cn&edition=full","pubTime":"2024-04-18 16:15","pubTimestamp":1713428148,"startTime":"0","endTime":"0","summary":"04月18日, 来凯医药-B股价跌6.98%，报收5.60元，成交金额3595万元，换手率1.55%，振幅11.96%，量比0.68。来凯医药-B今日主力资金净流出58万元，上一交易日主力净流出20万元，今日环比增加190.00%。该股近5个交易日上涨6.64%，主力资金累计净流入173万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入311万元，其中净流入天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404181616178b34bda6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404181616178b34bda6&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428555985","title":"来凯医药－Ｂ(02105)股价下跌5.15%，现价港币$5.71","url":"https://stock-news.laohu8.com/highlight/detail?id=2428555985","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2428555985?lang=zh_cn&edition=full","pubTime":"2024-04-18 15:28","pubTimestamp":1713425280,"startTime":"0","endTime":"0","summary":"[下跌股]来凯医药－Ｂ(02105) 股价在下午03:28比前收市价下跌5.15%，现股价为港币$5.71。至目前为止，今日最高价为$6.27，而最低价为$5.71。总成交量为540.6万股，总成交金额为港币$3.23千万。","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180126135515084_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180126135515084_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2404181185/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2428075339","title":"港股异动 | 来凯医药-B(02105)再涨超9% 治疗肥胖新药获美国FDA批准临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2428075339","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2428075339?lang=zh_cn&edition=full","pubTime":"2024-04-17 09:31","pubTimestamp":1713317517,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，来凯医药-B(02105)早盘再涨超9%，截至发稿，涨9.51%，报7.14港元，成交额600.72万港元。消息面上，来凯医药宣布，其自主研发的LAE102（ActRIIA单克隆抗体）已获得美国食品和药品管理局（FDA）的新药临床试验（IND）批准，用于治疗肥胖症患者。华创证券此前指出，全球首创的ActRIIA单抗LAE102能够增肌减脂，有潜力和GLP-1RA配合使用，市场潜力巨大并具备国际化价值。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1103673.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2427484721","title":"除了减重还能增肌？减肥药新靶点浮出水面 来凯医药股价坐上“过山车”","url":"https://stock-news.laohu8.com/highlight/detail?id=2427484721","media":"时代财经","top":-1,"share":"https://www.laohu8.com/m/news/2427484721?lang=zh_cn&edition=full","pubTime":"2024-04-16 18:57","pubTimestamp":1713265054,"startTime":"0","endTime":"0","summary":"减肥药依然是最激动人心的概念。4月15日午间，来凯医药（02105.HK）发布公告表示，公司已获得美国食品药品监督管理局（FDA）对于LAE102用于治疗肥胖适应症患者的新药临床试验（IND）批准。LAE102是来凯医药自主研发的针对ActRIIA的单克隆体。来凯医药表示，在临床前研究中，LAE102显示出增加肌肉并减少脂肪的效果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202404163047031629.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2427079314","title":"减肥新药获批！立马暴涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2427079314","media":"市场资讯","top":-1,"share":"https://www.laohu8.com/m/news/2427079314?lang=zh_cn&edition=full","pubTime":"2024-04-15 19:17","pubTimestamp":1713179820,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　另一方面，新“国九条”助力下，高铁基建、重型基建股领涨，中国中车大涨逾10%；石油股逆势上涨，中国石油股份涨超2%。　　4月15日，中国中车大涨超10%，报4.49港元，最新总市值2201亿港元。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/marketresearch/2024-04-15/doc-inarxkxs2446784.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2024-04-15/doc-inarxkxs2446784.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2427492720","title":"来凯医药-B(02105.HK)涨超64% 获美FDA批准LAE102治疗肥胖症患者的新药临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2427492720","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2427492720?lang=zh_cn&edition=full","pubTime":"2024-04-15 14:24","pubTimestamp":1713162284,"startTime":"0","endTime":"0","summary":"截至发稿， 来凯医药-B (02105.HK)涨64.24%，报7.9港元。该公司午间公布，集团已获得美国 食品 和药品管理局对于LAE102用于治疗肥胖适应症患者的IND批准，该药物是集团自主研发针对ActRIIA的单克隆抗体。LAE102是集团自主研发的一种单克隆抗体，针对参与调控肌肉再生和脂代谢的新靶点Act RIIA 。在临床前研究中，LAE102已显示出增加肌肉并减少脂肪的效果。LAE102与GLP-1受体激动剂联用可进一步减少脂肪并显着降低GLP-1受体激动剂导致的肌肉流失，使LAE102成为一种高质量体重控制候选药物，在减脂的同时保持肌肉质量。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240415143027877e171e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240415143027877e171e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427504569","title":"来凯医药-B午后飙升59% LAE102肥胖适应症新药临床试验获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2427504569","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2427504569?lang=zh_cn&edition=full","pubTime":"2024-04-15 13:59","pubTimestamp":1713160740,"startTime":"0","endTime":"0","summary":"　　来凯医药-B午后飙升59.04%，现报7.65港元，成交额8355.20万港元。　　来凯医药午间宣布，其自主研发的LAE102已获得美国食品和药品管理局的新药临床试验批准，用于治疗肥胖症患者。华创证券此前指出，全球首创的ActRIIA单抗LAE102能够增肌减脂，有潜力和GLP-1RA配合使用，市场潜力巨大并具备国际化价值。股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-04-15/doc-inarwyis6842363.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-04-15/doc-inarwyis6842363.shtml","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.laekna.com","stockEarnings":[{"period":"1week","weight":-0.0372},{"period":"1month","weight":0.1142},{"period":"3month","weight":0.4619},{"period":"6month","weight":-0.7167},{"period":"1year","weight":-0.5205},{"period":"ytd","weight":-0.701}],"compareEarnings":[{"period":"1week","weight":0.031},{"period":"1month","weight":0.0945},{"period":"3month","weight":0.1534},{"period":"6month","weight":0.0646},{"period":"1year","weight":-0.0782},{"period":"ytd","weight":0.0743}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"来凯医药有限公司是一家主要从事癌症及肝脏疾病创新疗法的发现、开发及商业化的投资控股公司。该公司主要从事单药疗法及联合疗法的候选药物的研发，专注用于治疗各种癌症及肝纤维化疾病。该公司的主要产品管线包括LAE002及LAE001。LAE002是一种三磷酸腺苷（ATP）竞争性AKT抑制剂，用于治疗卵巢癌、前列腺癌、乳腺癌及PD-1/PD-L1耐药实体瘤。LAE001是雄激素合成抑制剂，可同时抑制细胞色素P450家族17亚族A成员1（CYP17A1）及细胞色素P450家族11亚族B成员2（CYP11B2），用于治疗前列腺癌。该公司主要在中国、美国、欧洲及韩国市场开展业务。","exchange":"SEHK","name":"来凯医药-B","nameEN":"LAEKNA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"来凯医药-B(02105)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供来凯医药-B(02105)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"来凯医药-B,02105,来凯医药-B股票,来凯医药-B股票老虎,来凯医药-B股票老虎国际,来凯医药-B行情,来凯医药-B股票行情,来凯医药-B股价,来凯医药-B股市,来凯医药-B股票价格,来凯医药-B股票交易,来凯医药-B股票购买,来凯医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"来凯医药-B(02105)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供来凯医药-B(02105)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}